Cargando…

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

The 2018 US cholesterol management guidelines recommend additional lipid-lowering therapies for secondary prevention in patients with low-density lipoprotein cholesterol ≥70 mg/dL or non−high-density lipoprotein cholesterol ≥100 mg/dL despite maximum tolerated statin therapy. Such patients are consi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roe, Matthew T., Li, Qian H., Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Harrington, Robert A., Jukema, J. Wouter, Lopez-Jaramillo, Patricio, Lopes, Renato D., Louie, Michael J., Moriarty, Patrick M., Szarek, Michael, Vogel, Robert, White, Harvey D., Zeiher, Andreas M., Baccara-Dinet, Marie T., Steg, Ph. Gabriel, Schwartz, Gregory G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830944/ https://www.ncbi.nlm.nih.gov/pubmed/31475572 http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042551

Ejemplares similares

Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
por: Szarek, Michael, et al.
Publicado: (2020)

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
por: Jukema, J. Wouter, et al.
Publicado: (2019)

Effect of alirocumab on cataracts in patients with acute coronary syndromes
por: Suc, Gaspard, et al.
Publicado: (2023)

Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes
por: Suc, Gaspard, et al.
Publicado: (2023)

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
por: White, Harvey D, et al.
Publicado: (2019)

Alirocumab after acute coronary syndrome in patients with a history of heart failure
por: White, Harvey D, et al.
Publicado: (2021)

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
por: Sinnaeve, Peter R, et al.
Publicado: (2020)

Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
por: Schwartz, Gregory G., et al.
Publicado: (2020)

Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
por: Steg, Philippe Gabriel, et al.
Publicado: (2019)

Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
por: Bays, Harold E., et al.
Publicado: (2018)

Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan
por: Teramoto, Tamio, et al.
Publicado: (2019)

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial
por: Goodman, Shaun G., et al.
Publicado: (2023)

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
por: Tuñón, José, et al.
Publicado: (2020)

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
por: Schwartz, Gregory G, et al.
Publicado: (2023)

Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score–Matched Analysis of the ODYSSEY OUTCOMES Trial
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
por: Ginsberg, Henry N., et al.
Publicado: (2016)

Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
por: Ginsberg, Henry N., et al.
Publicado: (2018)

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
por: Langslet, Gisle, et al.
Publicado: (2020)

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
por: Nam, Chang-Wook, et al.
Publicado: (2019)

Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials
por: Leiter, L. A., et al.
Publicado: (2017)

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
por: Colhoun, Helen M., et al.
Publicado: (2016)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study
por: Bruckert, Eric, et al.
Publicado: (2022)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
por: Kastelein, John J. P., et al.
Publicado: (2014)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
por: Li, Haiyan, et al.
Publicado: (2020)

Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials
por: Mohammadi, Kusha A., et al.
Publicado: (2023)

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale
por: Teramoto, Tamio, et al.
Publicado: (2017)

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
por: Kastelein, John J.P., et al.
Publicado: (2015)

Categorical representation of North American precipitation projections
por: Greene, Arthur M., et al.
Publicado: (2016)

Evolution of the American College of Cardiology and American Heart Association Cardiology Clinical Practice Guidelines: A 10‐Year Assessment
por: DuBose‐Briski, Victoria, et al.
Publicado: (2019)

Hotline sessions presented at the American College of Cardiology Congress 2009
por: Maier, Lars S., et al.
Publicado: (2009)

Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations
por: Whelton, Paul K, et al.
Publicado: (2022)

Taking a Stand Against Air Pollution – The Impact on Cardiovascular Disease: A Joint Opinion from the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology
por: Brauer, Michael, et al.
Publicado: (2021)

Taking a Stand Against Air Pollution—The Impact on Cardiovascular Disease: A Joint Opinion from the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology
por: Brauer, Michael, et al.
Publicado: (2021)

Taking a stand against air pollution – the impact on cardiovascular disease: A Joint Opinion from the World Heart Federation, American College of Cardiology, American Heart Association, and the European Society of Cardiology
por: Brauer, Michael, et al.
Publicado: (2021)

Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology
por: German, Charles A., et al.
Publicado: (2022)

Geriatric cardiology at 62(nd) Scientific Sessions of American College of Cardiology 2013
por: Wehrmacher, William H.
Publicado: (2013)

Comparison of the Prognostic Usefulness of the European Society of Cardiology and American Heart Association/American College of Cardiology Foundation Risk Stratification Systems for Patients With Hypertrophic Cardiomyopathy
por: Leong, Kevin M.W., et al.
Publicado: (2018)

Evaluation and Management of Syncope: Comparing the Guidelines of the American College of Cardiology/American Heart Association/Heart Rhythm Society and the European Society of Cardiology
por: Williford, Noah N., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_aq8r6h85pli99let3j7jrjut93